Previous 10 | Next 10 |
Bayer's ( OTCPK:BAYRY ) ( OTCPK:BAYZF ) Q4 earnings and sales were driven by Crop Science and Consumer Health but Pharmaceuticals saw a decline. Meanwhile, the company noted that it expects FY 2023 earnings to be below previous year due to inflation and price factors. Q4...
Following four straight sessions of losses, oncology-focused biotech Replimune Group ( NASDAQ: REPL ) added ~7% on Monday after announcing a favorable response from the FDA regarding its Phase 2 trial CERPASS for lead asset RP1. The company has already completed patient enrollment...
Summary Regeneron has a respectable portfolio of commercialized medicines and is working on potentially transformative new technologies for immuno-oncology. Their collaborative energy is strong and the medium-term looks good, but a lot of their future hinges on emerging biotechnological...
Regeneron ( NASDAQ: REGN ) announced Friday that a group of EU medical experts recommended the marketing authorization of checkpoint receptor Libtayo with chemotherapy as a first-line option for PD-L1 positive non-small cell lung cancer (NSCLC). Specifically, the European Medicines Ag...
TARRYTOWN, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo ® (cemiplimab) in combination wi...
The US FDA has accepted for priority review Regeneron Pharamceuticals' ( NASDAQ: REGN ) a high-dose version -- 8 mg -- of its best-selling macular degeneration and diabetic macular edema (DME) treatment Eylea (aflibercept). The company, which markets the drug with Bayer AG ( OT...
BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA ® (aflibercept) Injection, with vast majority of patients maintaining extended dosing regimens through 48 weeks If approved, aflibercept 8 mg will be second ophthalmology medicine devel...
If approved, pozelimab would be the first and only treatment for those living with CHAPLE CHAPLE is an ultra-rare hereditary immune disease that causes overactivation of the complement system, leading to potentially life-threatening abdominal and cardiovascular symptoms TARRYTOWN,...
Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...
Regeneron Pharmaceuticals, Inc. (REGN) SVB Securities Global Biopharma Conference February 14, 2023 09:20 AM ET Company Participants Ryan Crowe - VP, IR Izzy Lowy - SVP of Clinical Development for Oncology Andres Sirulnik - SVP, Translational & Clinical Sciences, H...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...